Control of antigen-independent T-cell migration after HSCT.
作者信息
Koyama Motoko
机构信息
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA.
出版信息
Blood Adv. 2025 Jan 14;9(1):207-208. doi: 10.1182/bloodadvances.2024014584.
Abstract
摘要
相似文献
1
Control of antigen-independent T-cell migration after HSCT.异基因造血干细胞移植后抗原非依赖性T细胞迁移的调控
Blood Adv. 2025 Jan 14;9(1):207-208. doi: 10.1182/bloodadvances.2024014584.
2
Long-Term Survival and Immune Reconstitution of Donor-Derived Chimeric Antigen Receptor T-Cell Therapy for Childhood Molecular Relapse of B-Cell Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.异基因造血干细胞移植后儿童 B 细胞急性淋巴细胞白血病分子复发的供体嵌合抗原受体 T 细胞治疗的长期生存和免疫重建。
Pediatr Hematol Oncol. 2024 Nov;41(8):583-595. doi: 10.1080/08880018.2024.2408535. Epub 2024 Oct 3.
3
Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.人源化抗 CD19 CAR-T 细胞疗法和序贯异基因造血干细胞移植治疗难治/复发 B 淋巴细胞白血病的长期生存：CAR-T 细胞治疗的回顾性研究。
Front Immunol. 2021 Oct 29;12:755549. doi: 10.3389/fimmu.2021.755549. eCollection 2021.
4
Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation.在单倍体造血干细胞移植后 90 天内，HLA-A*0201/BMLF1 和 HLA-A*1101/LMP2 特异性 EBV 细胞毒性 T 淋巴细胞的免疫重建。
Virol J. 2019 Feb 8;16(1):19. doi: 10.1186/s12985-019-1123-y.
5
Antiviral potential of Vδ2 T cells in children given TCR αβ/CD19 cell-depleted HLA-haploidentical HSCT.接受TCR αβ/CD19细胞去除的HLA单倍型相合造血干细胞移植的儿童中Vδ2 T细胞的抗病毒潜力
Blood Adv. 2025 Mar 11;9(5):990-1002. doi: 10.1182/bloodadvances.2024013902.
6
Assessment of Patient-Specific Human Leukocyte Antigen Genomic Loss at Relapse After Antithymocyte Globulin-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplant.抗胸腺细胞球蛋白预处理的单倍体相合造血干细胞移植后复发时的患者特异性人类白细胞抗原基因组缺失评估
JAMA Netw Open. 2022 Apr 1;5(4):e226114. doi: 10.1001/jamanetworkopen.2022.6114.
7
Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission.病例报告：供体衍生的慢性淋巴细胞白血病嵌合抗原受体 T 细胞治疗缓解后复发/难治性急性髓系白血病桥接异基因造血干细胞移植。
Front Immunol. 2024 May 13;15:1389227. doi: 10.3389/fimmu.2024.1389227. eCollection 2024.
8
[CAR T-cell bridging to allo-HSCT for relapsed/refractory B-cell acute lymphoblastic leukemia: the follow-up outcomes].[嵌合抗原受体T细胞桥接异基因造血干细胞移植治疗复发/难治性B细胞急性淋巴细胞白血病：随访结果]
Zhonghua Xue Ye Xue Za Zhi. 2020 Sep 14;41(9):710-715. doi: 10.3760/cma.j.issn.0253-2727.2020.09.002.
9
Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy.异基因造血干细胞移植治疗髓系恶性肿瘤的患者对 COVID-19 mRNA 疫苗的特异性免疫反应会受到免疫抑制治疗的影响。
Leuk Res. 2023 Jul;130:107314. doi: 10.1016/j.leukres.2023.107314. Epub 2023 May 16.
10
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.序贯 CD7 CAR T 细胞治疗与异基因造血干细胞移植而不进行移植物抗宿主病预防。
N Engl J Med. 2024 Apr 25;390(16):1467-1480. doi: 10.1056/NEJMoa2313812.
本文引用的文献
1
Chemokine receptors are required for effector T-cell trafficking to GVHD tissues but not to bone marrow.趋化因子受体对于效应T细胞向移植物抗宿主病组织的迁移是必需的，但对于其向骨髓的迁移则不是必需的。
Blood Adv. 2025 Jan 14;9(1):209-221. doi: 10.1182/bloodadvances.2024013291.
2
Graft-versus-host disease is locally maintained in target tissues by resident progenitor-like T cells.移植物抗宿主病在靶组织中由驻留祖细胞样 T 细胞局部维持。
Immunity. 2023 Feb 14;56(2):369-385.e6. doi: 10.1016/j.immuni.2023.01.003. Epub 2023 Jan 30.
3
Current Concepts and Advances in Graft-Versus-Host Disease Immunology.当前移植物抗宿主病免疫学的概念和进展。
Annu Rev Immunol. 2021 Apr 26;39:19-49. doi: 10.1146/annurev-immunol-102119-073227. Epub 2021 Jan 11.
4
Cognate antigen directs CD8+ T cell migration to vascularized transplants.同源抗原指导 CD8+ T 细胞向血管化移植物迁移。
J Clin Invest. 2013 Jun;123(6):2663-71. doi: 10.1172/JCI66722. Epub 2013 May 15.
5
Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells.在缺乏功能性放射敏感的宿主造血衍生抗原呈递细胞的情况下，通过性别错配的 H-Y 抗原诱导急性移植物抗宿主病。
Blood. 2012 Apr 19;119(16):3844-53. doi: 10.1182/blood-2011-10-384057. Epub 2011 Nov 18.
6
Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting CC-chemokine receptor 7 on donor T cells.通过针对供体 T 细胞上的 CC 趋化因子受体 7 来分离移植物抗宿主病与移植物抗白血病反应。
Blood. 2010 Jun 10;115(23):4914-22. doi: 10.1182/blood-2009-08-239848. Epub 2010 Feb 25.
7
CCR2 is required for CD8-induced graft-versus-host disease.CCR2是CD8诱导的移植物抗宿主病所必需的。
Blood. 2005 Nov 1;106(9):3322-30. doi: 10.1182/blood-2005-05-1860. Epub 2005 Jul 21.
8
Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease.CCR5在急性移植物抗宿主病期间供体CD4+CD25+调节性T细胞功能中起关键作用。
Blood. 2005 Nov 1;106(9):3300-7. doi: 10.1182/blood-2005-04-1632. Epub 2005 Jul 7.
9
In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets.急性移植物抗宿主病早期事件的体内分析揭示了T细胞亚群的顺序性浸润。
Blood. 2005 Aug 1;106(3):1113-22. doi: 10.1182/blood-2005-02-0509. Epub 2005 Apr 26.
10
CCR6 regulates CD4+ T-cell-mediated acute graft-versus-host disease responses.CCR6调节CD4 + T细胞介导的急性移植物抗宿主病反应。
Blood. 2005 Jul 1;106(1):18-26. doi: 10.1182/blood-2004-08-2996. Epub 2005 Mar 17.
Zotero 插件